Company News

Company News
January 24, 2023
Core One Labs’ Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
Vancouver, British Columbia, Canada – January 24, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU)...
Read more
Company News
January 13, 2023
Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and other Drug Developers
Vancouver, British Columbia, Canada – January 13, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU)...
Read more
Company News
December 13, 2022
Core One Labs’ Subsidiary Vocan Biotechnologies Achieves Development Milestones
Vancouver, British Columbia, Canada – December 13, 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
November 25, 2022
CORE ONE LABS’ ANNOUNCES APPOINTMENT OF BF BORGERS CPA PC AS ITS NEW AUDITOR
Vancouver, British Columbia, Canada – November 25, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
November 18, 2022
Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
Vancouver, British Columbia, Canada – November 18, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
November 10, 2022
Core One Labs Announces Grant of Stock Options
Vancouver, British Columbia, Canada – November 10, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more